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To the Editor: Enterovirus infec-
tions are associated with many clini-
cal manifestations, and specific virus 
groups or serotypes are associated 
with specific manifestations. Cox-
sackievirus A16, a common cause of 
hand, foot and mouth disease, rarely 
causes encephalitis. Although most 
enterovirus infections are cleared by 
cellular immune responses, invasive 
enterovirus disease is prevented or 
controlled by neutralizing antibodies 
(1). Thus, patients with humoral im-
munodeficiencies are susceptible to 
serious enterovirus infections.
Nine cases of enteroviral en-
cephalitis (1 caused by echovirus 13, 
1 caused by coxsackievirus A16, 2 
caused by enterovirus 71, and 5 caused 
by unknown enteroviruses) have been 
reported after therapy with rituximab, 
a monoclonal antibody (MAb) that 
causes secondary hypogammaglobu-
linemia (2). We describe coxsackievi-
rus A16 encephalitis in a patient who 
was receiving treatment with the MAb 
obinutuzumab.
A 67-year-old woman with non-
Hodgkin lymphoma showed complete 
remission after 6 cycles of treatment 
with bendamustine and obinutuzum-
ab. Induction immunochemotherapy 
was followed by obinutuzumab main-
tenance therapy. At admission, she had 
received 7 of 12 scheduled treatments.
The patient was hospitalized be-
cause of a history of high-grade fever 
that did not respond to antimicrobial 
drugs, confusion, general weakness, 
and urinary incontinence. She had a 
neutrophil count of 3.1 × 109 cells/L 
but had severe lymphocytopenia (0.3 
× 109 cells/L and an absolute CD4 cell 
count of 0.082 × 109 cells/L) and low 
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serum immunoglobulin levels (IgG 
3.86 g/L [reference range 7.51–15.6 
g/L], IgA 0.07 g/L [reference range 
0.82–4.53 g/L], and IgM 0.13 g/L 
[reference range 0.46–3.04 g/L]). 
Cerebrospinal fluid (CSF) samples 
were collected on days 1, 4, and 6. 
CSF leukocyte counts increased from 
14 cells/mm3 (day 1) to 60 cells/mm3 
(day 4) (35% and 27% lymphocytes, 
respectively). Cytologic and immuno-
phenotypic analyses showed no cere-
bromeningeal lymphoma infiltration. 
Total protein levels in CSF increased 
from 561 mg/L on day 1 to 771 mg/L 
on days 4 and 6.
Bacterial and fungal cultures were 
negative. Cryptococcal antigen was 
not detected in CSF. Serologic test re-
sults were negative for Borrelia spp., 
Listeria spp., parvovirus B19, measles 
virus, and galactomannan. PCR results 
for CSF were repeatedly negative for 
herpes simplex virus, varicella zoster 
virus, cytomegalovirus, Toxoplasma 
gondii, JC polyomavirus, human her-
pesvirus 6, Epstein-Barr virus, and 
mumps virus. PCR results and cul-
ture were negative for Mycobacterium 
spp. Serum samples were negative for 
antibodies against neuronal nuclear 
(Hu, Ri, and Yo) antigens. However, 
enterovirus RNA was detected by re-
verse transcription PCR in all CSF 
samples. Sequencing of the virion 
protein 1 gene obtained directly from 
RNA extracted from CSF identified 
the virus as coxsackievirus A16 (3).
Computed tomography scan of 
the brain on day 2 showed no abnor-
malities. However, brain magnetic 
resonance imaging scans on the third 
and fourth days showed bilateral, 
multiple, hyperintense white matter 
lesions in the periventricular region 
and cerebral hemispheres. Treatment 
was started empirically with broad-
spectrum antimicrobial drugs and acy-
clovir; the acyclovir was stopped after 
infection with herpes simplex virus 
was excluded.
On day 4, imaging indicated 
development of aphasia and right 
hemiparesis without new lesions. 
The patient was transferred for me-
chanical ventilation after a grand mal 
seizure. Treatment with intravenous 
immune globulin (IVIG, 400 mg/kg) 
was started on day 4 and given for 
5 consecutive days, which resulted 
in marked and continued neurolog-
ic improvement. Monthly doses of 
IVIG (500 mg/kg) resulted in normal 
serum IgG levels. Four months af-
ter initial examination, the virus has 
been cleared but the patient still has 
intermittent confusion and language 
defects. Treatment with IVIG will be 
continued for an additional 6 months.
Use of MAbs against CD20 B-
cell antigen has become standard 
treatment for B-cell lymphomas and 
an increasing number of autoimmune 
disorders (4,5). However, resulting 
hypogammaglobulinemia predisposes 
patients to opportunistic infections, 
including progressive multifocal leu-
koencephalopathy and enterovirus 
infections (2,6). MAbs with enhanced 
activity against CD20 (e.g., obinutu-
zumab) have been developed. Obinu-
tuzumab has been approved by the 
US Food and Drug Administration 
for treatment of chronic lymphocytic 
leukemia. Studies regarding the use of 
obinutuzumab for other B-cell malig-
nancies are ongoing (7).
We anticipate that more cases 
of enteroviral encephalitis might de-
velop, given the increasingly frequent 
use of MAbs against CD20 and wide-
spread occurrence of enteroviruses. 
However, in view of the few reported 
cases (2), we also suspect that many 
cases remain undiagnosed despite 
availability of several pan-enterovirus 
diagnostic kits, which can detect low 
viral loads. Thus, clinicians should be 
suspicious of severe enterovirus infec-
tions in patients receiving MAbs.
Any patient receiving MAbs 
against CD20 who has neurologic 
symptoms should be screened for 
infection with enterovirus RNA. 
In contrast to JC polyomavirus– 
associated progressive multifocal 
leukoencephalopathy, enteroviral en-
cephalitis can be successfully treated 
by early administration of IVIG, which 
might contain neutralizing antibodies, 
albeit in variable amounts (8). In the 
absence of double-blinded, placebo-
controlled clinical studies of treatment 
for severe enterovirus infections, no 
specific antiviral therapy has been ap-
proved. However, 3 capsid inhibitors 
(pleconaril, pocapavir [V-073], and 
the pirodavir analog BTA-798) that 
show activity against enteroviruses 
are being developed (9). Pocapavir has 
potent activity against poliovirus and 
appears to be safe and well tolerated 
(10). In the United States, this drug is 
available by special request from the 
Food and Drug Administration.
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Serologic  
Evidence of  
Influenza A(H1N1)
pdm09 Virus  
Infection in Northern 
Sea Otters
To the Editor: Sporadic epizo-
otics of pneumonia among marine 
mammals have been associated with 
multiple animal-origin influenza A vi-
rus subtypes (1–6); seals are the only 
known nonhuman host for influenza 
B viruses (7). Recently, we reported 
serologic evidence of influenza A vi-
rus infection in free-ranging northern 
sea otters (Enhydra lutris kenyoni) 
captured off the coast of Washington, 
USA, in August 2011 (8). To inves-
tigate further which influenza A vi-
rus subtype infected these otters, we 
tested serum samples from these ot-
ters by ELISA for antibody-binding 
activity against 12 recombinant hem-
agglutinins (rHAs) from 7 influenza 
A hemagglutinin (HA) subtypes and 
2 lineages of influenza B virus (online 
Technical Appendix Table 1, wwwnc.
cdc.gov/EID/article/20/5/13-1890-
Techapp1.pdf). Estimated ages for the 
otters were 2–19 years (online Techni-
cal Appendix Table 2); we also tested 
archived serum samples from sea ot-
ters of similar ages collected from a 
study conducted during 2001–2002 
along the Washington coast (9). 
Of the 30 sea otter serum samples 
collected during 2011, a total of 21 
(70%) had detectable IgG (>200) for 
rHA of influenza A(H1N1)pdm09 vi-
rus (pH1N1) strain A/Texas/05/2009. 
Four of 7 serum samples that showed 
IgG ≥6,400 against pH1N1 rHA also 
showed low cross-reactivity (IgG 200) 
against rHA of A/Brisbane/59/2007, a 
previous seasonal influenza A(H1N1) 
virus (Figure, panel A; online Techni-
cal Appendix Table 1). No IgG was 
detected in any samples for any of the 
other 11 rHAs tested (IgG ≤100), and 
the sea otter serum samples collected 
during 2001–2002 did not react with 
any of the rHAs tested, including 
pH1N1 (IgG ≤100; Figure, panel A). 
Next, we tested serum samples by 
using a hemagglutination inhibition 
(HI) assay with whole influenza vi-
rus to detect strain-specific antibodies 
that inhibit receptor binding. Of the 30 
samples collected during 2011, a total 
of 22 (73%) showed HI antibody titers 
of ≥40 against pH1N1 virus. Titers 
against all other human and avian vi-
ruses tested were ≤10 for all samples 
by HI assay using turkey red blood 
cells (RBCs) (Figure, panel B; online 
Technical Appendix Table 3). No in-
fluenza A or B virus–specific HI an-
tibodies were detected in the samples 
collected during 2001–2002 (data not 
shown). Although nasal swab speci-
mens were collected from sea otters 
in the 2011 study, all specimens were 
negative for influenza virus by testing 
in embryonated eggs and by real-time 
PCR for detection of influenza A viral 
RNA (data not shown). These results 
suggest that sea otters were infected 
with influenza A virus sometime be-
fore the August 2011 sample collec-
tion date.
Although none of the 2011 sam-
ples showed HI titers to influenza A/
duck/New York/96 (H1N1) virus (dk/
NY/96) by testing using turkey RBCs 
(online Technical Appendix Table 2), 
titers against this strain were detected 
when using horse RBCs, which is a 
more sensitive means for the detec-
tion of mammalian antibodies against 
some avian influenza subtypes (10). Of 
the 22 samples that had HI titers >40 
to pH1N1 virus, 16 also had HI titers 
>40 against dk/NY/96 by horse RBC 
HI assay (online Technical Appen-
dix Table 2). However, titers against 
this strain were on average ≈4–8-fold 
lower than those for the pH1N1 virus 
strain, which suggests that that the ti-
ters against dk/NY/96 were the result 
of serologic cross-reactivity with avi-
an- and swine-origin pH1N1 viruses. 
To further test for cross-reactiv-
ity, 4 sea otter serum samples were 
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